Tag: neurogenetic testing market forecast

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Neurogenetic Testing Market CAGR Analysis And Future Market Development

The neurogenetic testing sector has experienced substantial expansion lately, projected to advance from a valuation of $0.7 billion in 2025 to $0.79 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 13.5%. This expansion during the past period was fueled by factors such as the initial embrace of polymerase chain reaction (PCR)-based genetic assessments, a growing incidence of hereditary neurological conditions, heightened utilization of microarray technologies, the progress in methods for earlier diagnosis, and the foundational incorporation of genetic screening into standard medical practices.

The neurogenetic testing sector is poised for substantial expansion, projected to reach $1.24 billion by 2030, reflecting a compound annual growth rate of 11.9%. This anticipated surge is fueled by a confluence of factors, including escalating demand for next-generation sequencing, broader application of clinical exome sequencing, heightened investments in genetic research, the ongoing development of sophisticated molecular diagnostic technologies, and an increasing embrace of personalized neurological treatment strategies. Key developments anticipated during this period involve the widespread adoption of whole-exome sequencing, a greater utilization of PCR-based neurological genetic tests, the enhanced implementation of microarray analysis, the increased testing capacity for rare neurological genetic conditions, and a growing emphasis on early detection and predictive testing methodologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Neurogenetic Testing Market Expansion Supported By Key Demand Factors

The escalating incidence of neurological conditions is anticipated to be a significant catalyst for the expansion of the neurogenetic testing market. Neurological disorders encompass a wide array of ailments impacting the intricate nervous system, which comprises the brain, spinal cord, and peripheral nerves. These conditions can arise from a combination of genetic predispositions, infectious agents, physical injuries, exposure to harmful substances, autoimmune reactions, and degenerative processes. By providing deep dives into an individual’s genetic predispositions, neurogenetic testing plays a crucial role in refining diagnoses, optimizing treatment strategies, and managing neurological disorders more effectively. This allows for tailored therapeutic approaches, informed decision-making regarding healthcare, and ultimately, an enhancement in patient care and overall outcomes. Demonstrating this trend, figures released in October 2023 by the World Federation of Neurology, a UK-based charity, revealed that neurological disorders have emerged as the second leading cause of mortality and the foremost contributor to disability globally, signifying a growing worldwide health challenge. Furthermore, over 40% of the global population was impacted in 2023, with projections indicating a near doubling of individuals living with brain diseases by 2050. Consequently, the increasing prevalence of neurological disorders is poised to fuel the growth trajectory of the neurogenetic testing market.

The growing prevalence of cancer is anticipated to be a key driver for the neurogenetic testing market’s expansion. Cancer is characterized by the uncontrolled proliferation of aberrant cells that invade and damage bodily tissues. Factors contributing to the rise in cancer cases include the widespread obesity epidemic, inherited genetic vulnerabilities, infections from viruses such as hepatitis B and C, the Epstein-Barr virus (EBV), and the human papillomavirus (HPV). Neurogenetic testing is instrumental in cancer management by aiding in the selection of the most efficacious treatment pathways, assessing patient prognoses, identifying individuals at higher risk, and facilitating personalized care plans tailored to each patient’s unique genetic makeup and family medical history. Illustrating this trend, data published in January 2024 by the American Cancer Society, a non-profit organization in the US, projected that the United States would record 2,001,140 new cancer diagnoses and 611,720 cancer-related fatalities in 2024, an increase from the 1,958,310 cases and 609,820 deaths reported in 2023. Thus, the escalating incidence of cancer is fundamentally propelling the neurogenetic testing market forward.

Neurogenetic Testing Market Segment Analysis Highlighting Growth Areas

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

Neurogenetic Testing Market Growth Trends Influencing Competitive Dynamics

Advancements in the neurogenetic testing sector are spearheaded by key players who are introducing novel solutions like whole-genome sequencing to broaden and refine genetic evaluations, paving the way for more thorough and customized diagnostics for neurological conditions. Whole-genome sequencing (WGS) represents a thorough genetic examination technique that maps out the full DNA sequence of an organism’s entire genetic makeup. As an illustration, a genetic analysis provider based in the United States named Nucleus Genomics introduced a DNA analysis offering in March 2024, which is designed to provide individuals with enhanced insight into their genetic leanings, thereby supporting well-informed healthcare choices. Nucleus Genomics, by leveraging state-of-the-art technology and professional genetic advisory services, is poised to transform the field of genetic diagnostics by making whole-genome sequencing accessible to individuals, thereby revolutionizing genomic medicine.

Neurogenetic Testing Market Leading Companies: Who Holds Significant Market Presence?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Access The Complete Neurogenetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Neurogenetic Testing Market Regional Distribution: Which Areas Drive Market Expansion?

North Americawas the largest region in the neurogenetic testing market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The Neurogenetic Testing Market?

The neurogenetic testing market has experienced rapid expansion in recent years. It is projected to increase from $0.7 billion in 2025 to $0.79 billion in 2026, with a compound annual growth rate (CAGR) of 13.5%. Historically, this growth can be attributed to the early adoption of PCR-based genetic testing, a rising prevalence of inherited neurological disorders, enhanced utilization of microarray platforms, the development of advanced early diagnostic techniques, and the initial integration of genetic screening into clinical workflows.

The neurogenetic testing market is poised for significant expansion in the coming years. Projections indicate it will reach $1.24 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This anticipated growth during the forecast period is fueled by several factors, including an escalating demand for next-generation sequencing, the expanding scope of clinical exome sequencing, increased capital allocation towards genetic research, the creation of sophisticated molecular diagnostic instruments, and the wider acceptance of tailored neurological treatment strategies. Key trends expected over the forecast horizon encompass a greater embrace of whole-exome sequencing technologies, a surge in the application of PCR-based neurological genetic assays, wider deployment of microarray analysis, an increase in screening for uncommon neurological genetic conditions, and a heightened need for prompt diagnosis and foresightful testing.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Which Strategic Drivers Are Supporting The Neurogenetic Testing Market Development?

An increasing incidence of neurological conditions is anticipated to fuel the expansion of the neurogenetic testing market. These conditions encompass any ailments impacting the nervous system, including the brain, spinal cord, and associated nerves. Their widespread occurrence stems from factors such as genetic susceptibility, infections, physical trauma, exposure to toxins, autoimmune reactions, and degenerative processes. Neurogenetic testing plays a crucial role in improving the diagnosis, therapeutic approaches, and overall management of neurological disorders. It achieves this by providing customized data on genetic risk factors, informing treatment strategies, and enabling individuals and their families to make well-informed healthcare decisions, ultimately leading to better patient care and results. As an illustration of this escalating global health concern, the World Federation of Neurology, a UK-based charitable organization, reported in October 2023 that neurological disorders have become the second-leading cause of death and the primary source of disability globally. In 2023, over 40 percent of the world’s population was affected, with projections indicating a near doubling in the number of individuals afflicted by brain disease by 2050. Consequently, the growing frequency of neurological disorders is expected to stimulate the expansion of the neurogenetic testing market.

What Segment Types Are Included In The Neurogenetic Testing Market Analysis?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

What Trends Are Shaping The Neurogenetic Testing Market Structure?

Leading companies in the neurofibromatosis type 1 (NF1) market are concentrating on introducing innovative products like kinase inhibitors to improve targeted treatment and patient outcomes. A kinase inhibitor is a drug type that obstructs the action of kinases, which are enzymes responsible for transferring phosphate groups to proteins, thereby regulating various cellular processes. For instance, in May 2023, AstraZeneca plc, a UK-based pharmaceutical industry company, obtained approval from China for Koselugo (selumetinib), intended for treating symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged three years and above who have neurofibromatosis type 1 (NF1). This approval expands the availability of specific treatment options for pediatric NF1 patients, improving disease management and enhancing their quality of life. The introduction of Koselugo (selumetinib) in China aligns with the growing focus on precision medicine, offering a non-surgical alternative for managing inoperable plexiform neurofibromas.

Which Companies Are Engaged In The Neurogenetic Testing Market Environment?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Access The Complete Neurogenetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Geographic Region Represents The Largest Neurogenetic Testing Market Share?

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurogenetic Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2026, By The Business Research Company

Idiopathic Pulmonary Fibrosis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Rare Neurological Disease Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Acoustic Neuroma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Neurogenetic Testing Market From 2026 To 2030?

The neurogenetic testing market has experienced rapid expansion in recent years. It is projected to climb from $0.7 billion in 2025 to $0.79 billion in 2026, advancing at a compound annual growth rate (CAGR) of 13.5%. The historical rise can be attributed to the early uptake of PCR-based genetic testing, an increasing prevalence of inherited neurological disorders, wider deployment of microarray platforms, the emergence of early diagnostic techniques, and the initial embedding of genetic screening into clinical workflows.

The neurogenetic testing market is set to experience rapid expansion over the next few years, with projections indicating it will reach $1.24 billion in 2030, driven by a compound annual growth rate (CAGR) of 11.9%. This growth in the forecast period is attributable to the increasing demand for next-generation sequencing, the expanding scope of clinical exome sequencing, rising investment in genetic research, the development of advanced molecular diagnostic tools, and the growing adoption of personalized neurological treatment approaches. Major trends anticipated during this period include the rising adoption of whole-exome sequencing technologies, an increasing use of PCR-based neurological genetic tests, the growing implementation of microarray analysis, an expansion of testing for rare neurological genetic disorders, and a growing demand for early diagnosis and predictive testing.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Which Key Drivers Are Affecting The Neurogenetic Testing Market Development?

The increasing occurrence of neurological conditions is anticipated to boost the expansion of the neurogenetic testing market. Neurological disorders are defined as illnesses impacting the nervous system, encompassing the brain, spinal cord, and associated nerves. Their widespread presence stems from factors such as genetic vulnerability, infections, physical injury, exposure to toxins, autoimmune reactions, and degenerative processes. Neurogenetic testing considerably improves the identification, therapy, and handling of neurological conditions. This is achieved by providing tailored information on genetic risk factors, aiding in treatment choices, and enabling patients and their families to make educated health decisions, ultimately leading to better patient care and results. For instance, in October 2023, according to the World Federation of Neurology, a UK-based charity, reflecting an accelerating global health burden, neurological disorders now represent the second-leading cause of death and the primary cause of disability worldwide, with more than 40 percent of the global population affected in 2023 and the number of individuals living with brain disease projected to nearly double by 2050. Consequently, the growing occurrence of neurological conditions is expected to fuel the expansion of the neurogenetic testing market.

What Are The Main Segments Within The Neurogenetic Testing Market Segment Structure?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

What Trends Are Transforming The Neurogenetic Testing Market?

Leading companies in the neurogenetic testing market are developing innovative solutions, such as whole-genome sequencing, to enhance the accuracy and scope of genetic analysis, allowing for more comprehensive and personalized testing for neurological disorders. Whole-genome sequencing (WGS) is a thorough genetic testing method that involves identifying the complete DNA sequence of an individual’s entire genome. For instance, in March 2024, Nucleus Genomics, a US-based company providing genetic analysis, launched a DNA analysis product. This platform aims to empower individuals with a deeper understanding of their genetic predispositions, facilitating informed decisions about their health and well-being. Utilizing cutting-edge technology and expert genetic counseling services, Nucleus Genomics is set to redefine the landscape of genetic testing, bringing the power of whole-genome sequencing directly to individuals and revolutionizing the field of genomic medicine.

Who Are The Companies Participating In The Neurogenetic Testing Market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Get The Full Neurogenetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Region Is The Top Contributor To The Neurogenetic Testing Market By Share?

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Neurogenetic Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2026, By The Business Research Company

Idiopathic Pulmonary Fibrosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Rare Neurological Disease Treatment Market Report

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Acoustic Neuroma Market Report

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Neurogenetic Testing Market By The End Of 2030?

The neurogenetic testing market has seen a rapid increase in its size over recent years. It is projected to expand from $0.7 billion in 2025 to $0.79 billion in 2026, driven by a compound annual growth rate (CAGR) of 13.5%. This historical growth can be attributed to several factors, including the early adoption of pcr-based genetic testing, the rising prevalence of inherited neurological disorders, the increased use of microarray platforms, the development of early diagnostic techniques, and the initial integration of genetic screening into clinical workflows.

The neurogenetic testing market is anticipated to experience significant expansion in the coming years. This market is projected to reach a size of $1.24 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This growth during the forecast period is primarily driven by factors such as the increasing demand for next-generation sequencing, the expanding use of clinical exome sequencing, greater investment in genetic research, the creation of advanced molecular diagnostic tools, and the increasing acceptance of personalized neurological treatment methods. Key trends anticipated during this period encompass the increasing integration of whole-exome sequencing technologies, the growing application of PCR-based neurological genetic tests, broader implementation of microarray analysis, the expansion of testing services for rare neurological genetic disorders, and a rising demand for early diagnosis and predictive testing capabilities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Neurogenetic Testing Market?

An increase in the occurrence of neurological disorders is anticipated to stimulate the expansion of the neurogenetic testing market. These disorders encompass various conditions impacting the nervous system, including the brain, spinal cord, and nerves. Their widespread presence is often attributed to genetic predispositions, infections, trauma, exposure to toxins, autoimmune reactions, and degenerative processes. Neurogenetic testing plays a crucial role in improving the diagnosis, treatment, and overall management of neurological disorders. It achieves this by providing individualized information on genetic risk factors, informing therapeutic choices, and enabling patients and their families to make well-informed healthcare decisions, ultimately leading to better patient care and results. For example, data from October 2023, released by the World Federation of Neurology, a UK-based charity, indicates the increasing global health burden. Neurological disorders are now the second-leading cause of death and the leading cause of disability globally. More than 40 percent of the world’s population was affected in 2023, and the number of people living with brain disease is expected to almost double by 2050. Consequently, the growing prevalence of neurological disorders is anticipated to fuel the expansion of the neurogenetic testing market.

Which Segment Classifications Shape The Neurogenetic Testing Market?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

Which Trends Are Shaping The Future Of The Neurogenetic Testing Market?

Major companies in the neurogenetic testing market are developing innovative products, such as whole-genome sequencing, to enhance the accuracy and scope of genetic analysis, facilitating more comprehensive and personalized testing for neurological disorders. Whole-genome sequencing (WGS) is an extensive genetic testing method that involves determining the complete DNA sequence of an individual’s entire genome. For instance, in March 2024, Nucleus Genomics, a US-based company providing genetic analysis, introduced a DNA analysis product. Through this platform, individuals gain a deeper understanding of their genetic predispositions, enabling informed decisions about their health and well-being. With cutting-edge technology and expert genetic counseling services, Nucleus Genomics is poised to redefine the genetic testing landscape, bringing the power of whole-genome sequencing directly to individuals and revolutionizing the field of genomic medicine.

Which Companies Are Expanding Their Footprint In The Neurogenetic Testing Market?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Read the full neurogenetic testing market report here:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Regions Are Projected To Dominate The Neurogenetic Testing Market In The Coming Years?

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurogenetic Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2026, By The Business Research Company

Idiopathic Pulmonary Fibrosis Global Market Report

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Rare Neurological Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Acoustic Neuroma Global Market Report

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the neurogenetic testing market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Neurogenetic Testing Market’s size between 2026 and 2030?

The neurogenetic testing market size has seen rapid expansion in recent years. This market is set to increase from $0.7 billion in 2025 to $0.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.5%. The market’s past growth can be attributed to the early adoption of PCR-based genetic testing, the rising incidence of inherited neurological disorders, the increased utilization of microarray platforms, advancements in early diagnostic techniques, and the initial integration of genetic screening into clinical workflows.

The neurogenetic testing market is anticipated to undergo significant growth in the upcoming years, with its valuation expected to reach $1.24 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.9%. This projected expansion during the forecast period is driven by factors such as the increasing demand for next-generation sequencing, the expanding application of clinical exome sequencing, a rise in investment dedicated to genetic research, the development of sophisticated molecular diagnostic tools, and the growing adoption of personalized neurological treatment approaches. Key trends for this period include the increased uptake of whole-exome sequencing technologies, a greater reliance on PCR-based neurological genetic tests, the broader implementation of microarray analysis, an expansion in testing capabilities for rare neurological genetic disorders, and a growing emphasis on early diagnosis and predictive testing.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Which Drivers Are Shaping Strategic Decisions In The Neurogenetic Testing Market?

An increase in the occurrence of neurological conditions is anticipated to fuel the expansion of the neurogenetic testing market. These conditions encompass any ailments impacting the nervous system, specifically the brain, spinal cord, and nerves. Their increasing occurrence can be attributed to factors such as genetic predisposition, infections, physical trauma, exposure to toxins, autoimmune reactions, and degenerative processes. Neurogenetic testing substantially improves the diagnosis, therapeutic approaches, and overall management of neurological disorders. It achieves this by providing individualized understanding of genetic predispositions, aiding in treatment selection, and enabling patients and their families to make well-informed health decisions, ultimately leading to better patient care and results. As an illustration, in October 2023, the World Federation of Neurology, a UK-based charity, reported that neurological disorders, indicating a rapidly growing global health burden, are now the second-leading cause of mortality and the primary contributor to disability globally. More than 40 percent of the world’s population was affected in 2023, and the count of people suffering from brain diseases is expected to nearly double by 2050. Consequently, the growing frequency of neurological disorders is set to stimulate the expansion of the neurogenetic testing market.

What Segment Classifications Make Up The Neurogenetic Testing Market?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

What Trends Are Expected To Impact The Competitive Landscape Of The Neurogenetic Testing Market?

Major companies within the neurogenetic testing market are actively developing innovative solutions, such as whole-genome sequencing, to improve the precision and extent of genetic analysis, thereby providing more thorough and individualized testing for neurological conditions. Whole-genome sequencing (WGS) represents a comprehensive genetic testing approach that involves mapping an individual’s entire DNA sequence. For example, in March 2024, Nucleus Genomics, a US-based company specializing in genetic analysis, introduced a new DNA analysis product. This platform is designed to furnish individuals with a deeper insight into their genetic predispositions, enabling them to make knowledgeable choices concerning their health and overall welfare. By combining state-of-the-art technology with expert genetic counseling services, Nucleus Genomics intends to reshape the field of genetic testing, making whole-genome sequencing directly available to people and revolutionizing genomic medicine.

Which Major Industry Participants Are Leading The Neurogenetic Testing Market Growth?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Neurogenetic Testing Market?

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurogenetic Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2026, By The Business Research Company

Dna Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/dna-testing-global-market-report

Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-testing-global-market-report

Prenatal And Newborn Genetic Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model